Systematic identification of signaling pathways with potential to confer anticancer drug resistanceColin A. Martz, Kris C. Wood, Kathleen Ottina et al.|Science Signaling|2014Cited by 199
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceKatherine R. Singleton, Kris C. Wood, Ophélia Maertens et al.|Cell Reports|2017Cited by 109
Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancerKevin Lin, Kris C. Wood, Justine C. Rutter et al.|Nature Genetics|2020Cited by 91
A Receptor Tyrosine Kinase Network Composed of Fibroblast Growth Factor Receptors, Epidermal Growth Factor Receptor, v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, and Hepatocyte Growth Factor Receptor Drives Growth and Survival of Head and Neck Squamous Carcinoma Cell LinesKatherine R. Singleton, Lynn E. Heasley|Molecular Pharmacology|2013Cited by 43
Drug dependence in cancer is exploitable by optimally constructed treatment holidaysJeff Maltas, Kevin B. Wood, Shane T. Killarney et al.|Nature Ecology & Evolution|2023Cited by 27